Caris MI – LINK Medical

Treating Your Cancer Smarter

Give yourself the best chance of finding the right treatment using the most advanced molecular profiling tools

Molecular profiling

Caris Molecular Intelligence performs thorough molecular testing on DNA, RNA and proteins, utilising the most technically advanced systems, including the world’s first AI predictors, to identify the biomarkers relevant for optimised treatment decisions in a patient’s tumour, and to compare the biomarkers with data from clinical studies around the world. This is a powerful asset to aid clinical decisions regarding individual cancer therapies. Caris Molecular Intelligence enables clinicians to:

Identify therapies with potential benefit

Identify therapies that may not have been considered

Determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs)

Match patients to clinical trials

What are biomarkers?

A biomarker is any physical characteristic of the human body that can be measured. Your blood pressure is a biomarker. A haemoglobin level is a biomarker. Some biomarkers can be linked to a particular diagnosis, to disease outcomes, or to response to medication or other therapy. In oncology, important biomarkers that can be measured include the DNA, RNA, and protein within a tumour. These biomarkers can be used to make a diagnosis, to predict cancer aggressiveness, or to predict that a particular therapy will be effective.

DNA

DNA (deoxyribonucleic acid) is a molecule inside the cell that carries genetic information and passes it on from one generation to the next. DNA biomarkers can be evaluated for aberrations such as gene mutations or copy number alterations (e.g. gene amplification) that can cause a cancer cell to proliferate.

RNA

RNA (ribonucleic acid) contains information that has been copied from DNA. RNA biomarkers can be interrogated for gene fusions or a clinically relevant variant transcript which are commonly matched with FDA-approved medications.

Proteins

Proteins are comprised of amino acids. In normal cells, they support proper body functioning and are the basis of body structures such as skin and hair. In cancer, evaluating protein expression provides information on cancer type, optimal treatment, and can assess treatment efficacy.

Technology

Whole Exome Sequencing (22,000 gene mutations), Whole Transcriptome Sequencing (22,000 gene fusions), IHC’s (up to 15 tumour specific proteins), plus world’s first AI predictors using biomarker signatures.

Best in class Illumina sequencing technology (source: Maetens 2017)
Centralised analysis in one lab worldwide for quality control and the highest level of human expertise
Tumour microdissection for greater accuracy conducted on every case
Clinical trials connector, connects patients with relevant and active clinical trials in line with their diagnosis

Proven Use of AI in the Clinical Setting

Caris is able to create highly accurate AI algorithms from a world leading database that includes 260,000 Caris Molecular profiling case results out of which 215,000 cases have matched clinical outcome data. Caris has pioneered the first commercialised AI products currently available for use in oncology practice.

FOLFOXai – first line treatment (FOLFOX or FOLFIRI) for mCrC patients

Using two independent data sets (real-world evidence and Phase III TRIBE2 study data), MI FOLFOXai™ demonstrated that the overall survival (OS) of patients treated in a manner consistent with the FOLFOXai prediction was 17.5 months longer (71%) than the OS of patients treated counter to the prediction. Find MI FOLFOXai validation data here.

GPSai - of treating CUP and ambiguous cancers

Caris Life Sciences Accurately Identifies 21 Cancer Types Using Artificial Intelligence Derived Molecular Signatures to aid the diagnosis of CUP patients

Results from published data:

MI GPSai predicted the tumour type out of 21 options in the labelled data set with an accuracy of over 94%-97%.

Algorithm trained on molecular data from 57,489 cases and validated on 19,555 cases.

(Source: Abraham et al 2021)

The Caris Mollecular Tumor Board enables physicians to post a report and get feedback, advice and treatment recommendations from leading specialists around the world.

More information here

The Caris advantage

How it works

Contact LINK Medical on info@linkmedicalsolutions.com

Email now

LINK Medical will send requisition form to treating physician.

LINK Medical will obtain consent form and terms of service from patient.

LINK Medical will arrange packaging and collection of the patient's specimen sample.

Caris completes multi-genomic profiling.

Report is sent directly to treating physician. Report sent to patient upon request.

Download sample report

1 to 1 telephone meeting is offered to the treating physician directly.

Who can benefit from Caris?

Caris is for metastatic cancer patients that want a treatment pathway that is personalised for them.

Caris offers 2 products:

MI Profile (WES, WTS, IHC’s plus Folfox predictor and CUP predictor)
MI Tumor SEEK (WES, WTS, PDL-1 and MMR [no additional IHC’s], plus Folfox predictor and CUP predictor)

Evidence

Caris has an extensive database of publications, over 165 peer-reviewed manuscripts, which may be found here: https://www.carislifesciences.com/publications/

Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.